Home > Insider Trading > Filing (0001209191-16-126266)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	Pharmaceutical Preparations (2834)	452437375

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1664690	A. Charles Deignan	C/O Clearside Biomedical, Inc. 1220 Old Alpharetta Road, Suite 300 Alpharetta GA 30005	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-06-07	4,261	$0.00	62,291	No	4	C	Direct
Common Stock	Acquisiton	2016-06-07	470	$0.02	62,761	No	4	X	Direct
Common Stock	Disposition	2016-06-07	2	$7.00	62,759	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2016-06-07	9,375	$0.00	4,261	$0.00
Common Stock	Warrant to Purchase Common Stock (right to buy)	Disposition	2016-06-07	470	$0.00	470	$0.02

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0	2014-04-28		No	4	X	Direct

Footnotes

Represents shares received upon conversion of shares of Series B Preferred Stock.
Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock automatically converted into 0.454545 shares of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
On June 7, 2016, the reporting person exercised a warrant to purchase 470 shares of Issuer's common stock for $0.022 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 2 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 468 shares.
This warrant would have expired upon the closing of the Issuer's initial public offering.